Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer

被引:0
|
作者
Zhang, Leiming [1 ,2 ]
Yu, Zehao [2 ]
Jin, Rong [1 ,2 ]
Yang, Xuanang [2 ]
Ying, Dongjian [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Minimally Invas Surg, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Postoperative; Model prediction; DUCTAL ADENOCARCINOMA; SURGERY; 5-FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CONSENSUS; THERAPY;
D O I
10.1007/s00432-023-05071-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSurgery represents a primary therapeutic approach for borderline resectable and locally advanced pancreatic cancer (BR/LAPC). However, BR/LAPC lesions exhibit high heterogeneity and not all BR/LAPC patients who undergo surgery can derive beneficial outcomes. The present study aims to employ machine learning (ML) algorithms to identify those who would obtain benefits from the primary tumor surgery.MethodsWe retrieved clinical data of patients with BR/LAPC from the Surveillance, Epidemiology, and End Results (SEER) database and classified them into surgery and non-surgery groups based on primary tumor surgery status. To eliminate confounding factors, propensity score matching (PSM) was employed. We hypothesized that patients who underwent surgery and had a longer median cancer-specific survival (CSS) than those who did not undergo surgery would certainly benefit from surgical intervention. Clinical and pathological features were utilized to construct six ML models, and model effectiveness was compared through measures such as the area under curve (AUC), calibration plots, and decision curve analysis (DCA). We selected the best-performing algorithm (i.e., XGBoost) to predict postoperative benefits. The SHapley Additive exPlanations (SHAP) approach was used to interpret the XGBoost model. Additionally, data from 53 Chinese patients prospectively collected was used for external validation of the model.ResultsAccording to the results of the tenfold cross-validation in the training cohort, the XGBoost model yielded the best performance (AUC = 0.823, 95%CI 0.707-0.938). The internal (74.3% accuracy) and external (84.3% accuracy) validation demonstrated the generalizability of the model. The SHAP analysis provided explanations independent of the model, highlighting important factors related to postoperative survival benefits in BR/LAPC, with age, chemotherapy, and radiation therapy being the top three important factors.ConclusionBy integrating of ML algorithms and clinical data, we have established a highly efficient model to facilitate clinical decision-making and assist clinicians in selecting the population that would benefit from surgery.
引用
收藏
页码:11857 / 11871
页数:15
相关论文
共 50 条
  • [21] Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer
    Mancini, Brandon R.
    Stein, Stacey
    Lloyd, Shane
    Rutter, Charles E.
    James, Edward
    Chang, Bryan W.
    Lacy, Jill
    Johung, Kimberly L.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (06) : 982 - 988
  • [22] Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer
    Shaib, Walid L.
    Ip, Andrew
    Cardona, Kenneth
    Alese, Olatunji B.
    Maithel, Shishir K.
    Kooby, David
    Landry, Jerome
    El-Rayes, Bassel F.
    ONCOLOGIST, 2016, 21 (02): : 178 - 187
  • [23] REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives
    Boggi, Ugo
    Kauffmann, Emanuele F.
    Napoli, Niccolo
    Barreto, S. George
    Besselink, Marc G.
    Fusai, Giuseppe K.
    Hackert, Thilo
    Hilal, Mohammad Abu
    Marchegiani, Giovanni
    Salvia, Roberto
    Shrikhande, Shailesh V.
    Truty, Mark
    Werner, Jens
    Wolfgang, Christopher
    Bannone, Elisa
    Capretti, Giovanni
    Cattelani, Alice
    Coppola, Alessandro
    Cucchetti, Alessandro
    De Sio, Davide
    Di Dato, Armando
    Di Meo, Giovanna
    Fiorillo, Claudio
    Gianfaldoni, Cesare
    Ginesini, Michael
    Salinas, Camila Hidalgo
    Lai, Quirino
    Miccoli, Mario
    Montorsi, Roberto
    Pagnanelli, Michele
    Poli, Andrea
    Ricci, Claudio
    Sucameli, Francesco
    Tamburrino, Domenico
    Viti, Virginia
    Cameron, John
    Clavien, Pierre-Alain
    Asbun, Horacio J.
    UPDATES IN SURGERY, 2024, 76 (05) : 1573 - 1591
  • [24] Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
    Choi, Jin Ho
    Kim, Min Kyu
    Lee, Sang Hyub
    Park, Jin Woo
    Park, Namyoung
    Cho, In Rae
    Ryu, Ji Kon
    Kim, Yong-Tae
    Jang, Jin-Young
    Kwon, Wooil
    Kim, Hongbeom
    Paik, Woo Hyun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis
    Barenboim, Alex
    Lahat, Guy
    Geva, Ravit
    Nachmany, Ido
    Nakache, Richard
    Goykhman, Yaacov
    Brazowski, Eli
    Rosen, Galia
    Isakov, Ofer
    Wolf, Ido
    Klausner, Joseph M.
    Lubezky, Nir
    EJSO, 2018, 44 (10): : 1619 - 1623
  • [26] Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer
    Groot, Vincent P.
    Blair, Alex B.
    Gemenetzis, Georgios
    Ding, Ding
    Burkhart, Richard A.
    Yu, Jun
    Rinkes, Inne H. M. Borel
    Molenaar, I. Quintus
    Cameron, John L.
    Weiss, Matthew J.
    Wolfgang, Christopher L.
    He, Jin
    EJSO, 2019, 45 (09): : 1674 - 1683
  • [27] The role of systemic therapy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma
    Lo, Victor C. K.
    Goodwin, Rachel A.
    Vickers, Michael M.
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
  • [28] Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
    Luís Filipe Abreu de Carvalho
    Filip Gryspeerdt
    Niki Rashidian
    Kobe Van Hove
    Lambertine Maertens
    Suzane Ribeiro
    Anne Hoorens
    Frederik Berrevoet
    BMC Surgery, 23
  • [29] Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer
    Hartwig, W.
    Gluth, A.
    Hinz, U.
    Koliogiannis, D.
    Strobel, O.
    Hackert, T.
    Werner, J.
    Buechler, M. W.
    BRITISH JOURNAL OF SURGERY, 2016, 103 (12) : 1683 - 1694
  • [30] Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients
    Botta, Gregory P.
    Huynh, Tridu R.
    Spierling-Bagsic, Samantha R.
    Agelidis, Alexander
    Schaffer, Randolph
    Lin, Ray
    Sigal, Darren
    CANCER MEDICINE, 2023, 12 (07): : 7713 - 7723